BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34797453)

  • 1. Early Progressing Follicular Lymphoma.
    Wallace D; Casulo C
    Curr Oncol Rep; 2021 Nov; 23(12):149. PubMed ID: 34797453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. When to Use Targeted Therapy for the Treatment of Follicular Lymphoma.
    Nastoupil LJ
    Curr Hematol Malig Rep; 2021 Feb; 16(1):45-51. PubMed ID: 33797691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life.
    Sortais C; Lok A; Tessoulin B; Gastinne T; Mahé B; Dubruille V; Blin N; Touzeau C; Moreau A; Bossard C; Peterlin P; Garnier A; Guillaume T; Le Bourgeois A; Chevallier P; Moreau P; Leux C; Le Gouill S
    Ann Hematol; 2020 Jul; 99(7):1595-1604. PubMed ID: 32417940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma.
    Chin CK; Nastoupil LJ
    Hematol Oncol Clin North Am; 2020 Aug; 34(4):743-756. PubMed ID: 32586578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Divergent paths: management of early relapsed follicular lymphoma.
    Takiar R; Karimi Y; Phillips TJ
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):666-675. PubMed ID: 36485106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
    Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
    Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometry.
    Liu L; Yu X; Li Z; He X; Zha J; Lin Z; Hong Y; Zheng H; Lai Q; Ding K; Jia X; Fu G; Yu H; Yang H; Li Z; Young KH; Xu B
    J Hematol Oncol; 2022 Aug; 15(1):115. PubMed ID: 35996180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.
    Jurinovic V; Kridel R; Staiger AM; Szczepanowski M; Horn H; Dreyling MH; Rosenwald A; Ott G; Klapper W; Zelenetz AD; Barr PM; Friedberg JW; Ansell S; Sehn LH; Connors JM; Gascoyne RD; Hiddemann W; Unterhalt M; Weinstock DM; Weigert O
    Blood; 2016 Aug; 128(8):1112-20. PubMed ID: 27418643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How I treat early-relapsing follicular lymphoma.
    Casulo C; Barr PM
    Blood; 2019 Apr; 133(14):1540-1547. PubMed ID: 30700421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration.
    Tobin JWD; Keane C; Gunawardana J; Mollee P; Birch S; Hoang T; Lee J; Li L; Huang L; Murigneux V; Fink JL; Matigian N; Vari F; Francis S; Kridel R; Weigert O; Haebe S; Jurinovic V; Klapper W; Steidl C; Sehn LH; Law SC; Wykes MN; Gandhi MK
    J Clin Oncol; 2019 Dec; 37(34):3300-3309. PubMed ID: 31461379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression of disease within 24 months of initial therapy (POD24) detected incidentally in imaging does not necessarily indicate worse outcome.
    Bitansky G; Avigdor A; Vasilev E; Zlotnick M; Ribakovsky E; Benjamini O; Nagler A; Kedmi M
    Leuk Lymphoma; 2020 Nov; 61(11):2645-2651. PubMed ID: 32643497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Therapies for Follicular Lymphoma.
    Girard J; Karimi Y; Carty S; Wilcox R; Kaminiski M; Malek S; Phillips T
    Curr Hematol Malig Rep; 2021 Feb; 16(1):25-31. PubMed ID: 33754292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.
    Casulo C; Dixon JG; Le-Rademacher J; Hoster E; Hochster HS; Hiddemann W; Marcus R; Kimby E; Herold M; Sebban C; Gyan E; Foon K; Nielsen T; Vitolo U; Salles GA; Shi Q; Flowers CR
    Blood; 2022 Mar; 139(11):1684-1693. PubMed ID: 34614146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma.
    Freeman CL; Kridel R; Moccia AA; Savage KJ; Villa DR; Scott DW; Gerrie AS; Ferguson D; Cafferty F; Slack GW; Farinha P; Skinnider B; Connors JM; Sehn LH
    Blood; 2019 Aug; 134(9):761-764. PubMed ID: 31300404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel agents for relapsed and refractory follicular lymphoma.
    Cheah CY; Fowler NH
    Best Pract Res Clin Haematol; 2018 Mar; 31(1):41-48. PubMed ID: 29452665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Progression of Follicular Lymphoma: Biology and Treatment.
    Lipof JJ; Barr PM
    Hematol Oncol Clin North Am; 2020 Aug; 34(4):757-769. PubMed ID: 32586579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follicular lymphoma: Update on management and emerging therapies at the dawn of the new decade.
    Apostolidis J; Mokhtar N; Al Omari R; Darweesh M; Al Hashmi H
    Hematol Oncol; 2020 Aug; 38(3):213-222. PubMed ID: 31891210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma.
    Cheson BD; Morschhauser F; Martin P
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):563-571. PubMed ID: 32303486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK).
    Moccia AA; Schär S; Hayoz S; Pirosa MC; Taverna C; Novak U; Kimby E; Ghielmini M; Zucca E
    Br J Haematol; 2021 Mar; 192(6):1031-1034. PubMed ID: 32805081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphatidylinositol-3-Kinase Inhibition in Follicular Lymphoma.
    Lynch RC; Gopal AK
    Hematol Oncol Clin North Am; 2020 Aug; 34(4):727-741. PubMed ID: 32586577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.